Investigation of a tumour enzyme as a predictor of patient response to an Australian anti-cancer drug

研究肿瘤酶作为患者对澳大利亚抗癌药物反应的预测因子

• 批准号: nhmrc : 630584
• 负责人: Dr Hendrik-Tobias Arkenau
• 金额: $ 24.14万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/investigation-tumour-enzyme-cancer-drug/97005
• 关键词: Investigation; tumour; enzyme; predictor; patient

GSAO is a new cancer drug we have developed that is currently being trialed in cancer patients. Our investigation of how GSAO works has revealed that it needs to be activated by an enzyme expressed by certain types of cancers. This finding implies that GSAO should be more effective against cancers that make this enzyme. Our aim is to establish this concept in laboratory based experiments as a basis for selection of patients who are more likely to benefit from GSAO treatment.

GSAO是我们开发的一种新的癌症药物，目前正在癌症患者中进行试验。我们对GSAO如何工作的研究表明，它需要被某些类型的癌症表达的酶激活。这一发现意味着GSAO应该对制造这种酶的癌症更有效。我们的目的是在实验室基础上建立这一概念，作为选择更有可能从GSAO治疗中获益的患者的基础。